To determine the clinical consequences and it’s associated costs of the usage of oral anticoagulation therapy for the treatment of atrial fibrillation (AF) in Colombia by establishing the cost per disease related event. We used a 6-week cycle length, 17 functional state Markov model of the main clinical outcomes in the lifetime of a hypothetical cohort of 1,000 patient with AF per treatment arm. The pivotal clinical studies for apixaban, dabigatran, rivaroxaban compared to warfarin were the source of safety and efficacy data. Data for the analysis was extracted from this literature using indirect comparison methods. Costs in Colombian pesos 2012 are expressed in American dollars (1 US$ = COP$ 1785). To estimate costs, we analyzed resource use of a sample of 53 stroke, 148 myocardial infarction, 6 systemic embolism patients in San Ignacio University Hospital. Results were validated by an expert panel. The number of events associated with each anticoagulant therapy (apixaban, dabigatran 110mg, dabigatran 150mg, rivaroxaban and warfarin, respectively) were: stroke and systemic embolism 349, 363, 351, 360, 369. ISTH major bleedings 235, 212, 233, 280, 277; clinically relevant non major bleedings 342, 337, 357, 395, 383; myocardial infarctions 102, 114, 116, 101, 104; and event related deaths 459, 485, 475, 469, 481. Apixaban could be associated with savings in non pharmacological cost of $ 360, $170, $145 and $311 per treated patient compared to dabigatran 110mg, dabigatran 150mg , rivaroxaban and warfarin, respectively. In this non-pharmacological cost avoidance assessment we determined that apixaban can be a cost saving alternative in the long term. Versus SoC (warfarin), apixaban may be the only NOAC with consistent benefit on all relevant events. Consistent with trial data, lifetime modeling suggested reduction in the mortality.